Show simple item record

dc.contributor.authorMorris, JKen_US
dc.contributor.authorGarne, Een_US
dc.contributor.authorLoane, Men_US
dc.contributor.authorAddor, M-Cen_US
dc.contributor.authorBarisic, Ien_US
dc.contributor.authorBianchi, Fen_US
dc.contributor.authorGatt, Men_US
dc.contributor.authorLanzoni, Men_US
dc.contributor.authorLynch, Cen_US
dc.contributor.authorMokoroa, Oen_US
dc.contributor.authorNelen, Ven_US
dc.contributor.authorNeville, Aen_US
dc.contributor.authorO'Mahony, MTen_US
dc.contributor.authorRandrianaivo-Ranjatoelina, Hen_US
dc.contributor.authorRissmann, Aen_US
dc.contributor.authorTucker, Den_US
dc.contributor.authorde Walle, HEKen_US
dc.contributor.authorZymak-Zakutnia, Nen_US
dc.contributor.authorRankin, Jen_US
dc.date.accessioned2018-07-20T17:16:39Z
dc.date.available2018-05-08en_US
dc.date.issued2018-09en_US
dc.date.submitted2018-06-05T16:04:15.451Z
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/42427
dc.description.abstractWomen with epilepsy need to continue to take anticonvulsants during their pregnancies to prevent seizures from occurring. Since the 1980's, it has been known that the use of valproate (an anticonvulsant) in the first trimester of pregnancy is associated with an increased risk of spina bifida. Recent studies have also demonstrated increased risks of other congenital anomalies as well as a risk of cognitive impairment. Doctors in the EU are now advised not to prescribe valproate in pregnant women, in women who can become pregnant or in girls unless other treatments are ineffective or not tolerated. This study aimed to determine if there has been a reduction in the numbers of babies born with valproate syndrome in Europe from 2005 to 2014. Data from 15 European congenital anomaly registries, who are members of EUROCAT (A European network of population-based registries for the epidemiologic surveillance of congenital anomalies), identified 28 cases of valproate syndrome in 2.74 million births from 2005 to 2014. The prevalence of valproate syndrome in Europe significantly decreased from 0.22 per 10,000 births in 2005/6 to 0.03 per 10,000 births in 2013/14. One registry, Ile de la Reunion, had the majority of cases (17). After excluding these cases there still remained a decreasing trend even though it no longer reached statistical significance due to the small number of cases. This study emphasises the continued need for European collaboration in analysing rare exposures and rare anomalies.en_US
dc.description.sponsorshipEUROCAT registries are funded as fully described in Paper 6 of Report 9 - EUROCAT Member Registries: Organization and Activitiesen_US
dc.format.extent479 - 482en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofEur J Med Geneten_US
dc.rights© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCongenital anomalyen_US
dc.subjectSodium valproateen_US
dc.subjectValproic aciden_US
dc.subjectAdulten_US
dc.subjectAnticonvulsantsen_US
dc.subjectCognitive Dysfunctionen_US
dc.subjectCongenital Abnormalitiesen_US
dc.subjectEpilepsyen_US
dc.subjectEuropeen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectPregnancyen_US
dc.subjectPregnancy Complicationsen_US
dc.subjectRegistriesen_US
dc.subjectSyndromeen_US
dc.subjectValproic Aciden_US
dc.titlePrevalence of valproate syndrome in Europe from 2005 to 2014: A registry based multi-centre study.en_US
dc.typeArticle
dc.identifier.doi10.1016/j.ejmg.2018.05.008en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/29753923en_US
pubs.issue9en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume61en_US
dcterms.dateAccepted2018-05-08en_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record